目的 探討茵梔黃顆粒聯(lián)合人血丙種球蛋白治療新生兒ABO溶血性黃疸的臨床療效。方法 選取2014年5月-2016年5月月在合肥市濱湖醫(yī)院接受治療的ABO溶血性黃疸患兒80例，根據(jù)治療方法的不同分為對(duì)照組（40例）和治療組（40例）。對(duì)照組患兒靜脈滴注靜注人免疫球蛋白（pH 4）治療，劑量為1 g/（kg·d）。治療組在對(duì)照組的基礎(chǔ)上口服茵梔黃顆粒，1 g/次，3次/d。兩組患兒均治療3 d。比較兩組患兒治療前后臨床療效、血清指標(biāo)變化以及新生兒神經(jīng)行為（NBNA）和GESELL評(píng)分。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.00%、97.50%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患兒血清總膽紅素（TBIL）水平顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組患兒血清TBIL水平顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患兒NBNA評(píng)分均顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后治療組NBNA和GESELL評(píng)分升高幅度顯著好于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 茵梔黃顆粒聯(lián)合人血丙種球蛋白治療新生兒ABO溶血性黃疸具有很好的臨床效果，可有效降低膽紅素水平，促進(jìn)患兒生長(zhǎng)發(fā)育，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Yinzhihuang Granules combined with human immunoglobulin in treatment of neonatal ABO hemolytic jaundice. Methods Children (80 cases) with ABO hemolytic jaundice in Hefei Binhu Hospital from May 2014 to May 2016 were divided into control (40 cases) and treatment (40 cases) groups based on different treatments. Children in the control group were iv administered with human immunoglobulin (pH 4) for iv injection, 1 g/(kg·d). Patients in the treatment group were po administered with Yinzhihuang Granules on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 3 d. After treatment, the clinical efficacy, serum indexes, NBNA, and GESELL scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.00% and 97.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, the serum TBIL levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). The serum TBIL levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the NBNA scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the NBNA and GESELL scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Yinzhihuang Granules combined with human immunoglobulin has good clinical effect in treatment of neonatal ABO hemolytic jaundice, can effectively reduce the bilirubin level and promote the growth and development of children, which has a certain clinical application value.